You are here

TRANSPOSAGEN BIOPHARMACEUTICALS, INC.

Company Information
Address
201 West Second St.
Lexington, KY 40507-1112
United States


http://www.transposagenbio.com

Information

UEI: N/A

# of Employees: 15


Ownership Information

HUBZone Owned: No

Socially and Economically Disadvantaged: No

Woman Owned: No



Award Charts




Award Listing

  1. Novel reporter cell lines for neurotoxicant assays

    Amount: $225,000.00

    DESCRIPTION (provided by applicant): While it has been demonstrated that gene mutations are associated with an increasing number of neurodegenerative syndromes, environmental neurotoxicants remain a k ...

    SBIRPhase I2014Department of Health and Human Services National Institutes of Health
  2. Novel method to create knockout rats using endonucleases and spermatogonial stem

    Amount: $774,736.00

    DESCRIPTION provided by applicant The laboratory rat is a preferred rodent model in pre clinical drug studies Their larger size facilitates procedures otherwise difficult in mice includng studies ...

    SBIRPhase II2014Department of Health and Human Services National Institutes of Health
  3. Novel method to create knockout rats using endonucleases and spermatagonialstem

    Amount: $342,046.00

    DESCRIPTION (provided by applicant): The laboratory rat is the preferred rodent model in pre-clinical drug studies and encompasses the bulk of accumulated knowledge in drug development. Their larger s ...

    SBIRPhase I2011Department of Health and Human Services National Institutes of Health
  4. Generation of Site-Specific Recombinase-Expressing Transgenic Rats using an Enhan

    Amount: $240,637.00

    DESCRIPTION (provided by applicant): The goal is to create site-specific recombinase (SSR)-expressing transgenic rats in an efficient and unbiased manner through a transposon-mediated in vivo gene ...

    SBIRPhase I2010Department of Health and Human Services National Institutes of Health
  5. Creation of hyperactive transposons for mutagenesis in rodents

    Amount: $1,647,590.00

    DESCRIPTION (provided by applicant): The rat is a favored model for many types of human disease for which mice are not suitable. As opposed to the mouse, rats and humans also share more similarity in ...

    SBIRPhase II2010Department of Health and Human Services National Institutes of Health
  6. Novel SCID rat models for human cell transplantation studies

    Amount: $174,707.00

    DESCRIPTION (provided by applicant): The laboratory rat is used extensively by the pharmaceutical industry for preclinical animal efficacy and toxicology studies. In addition, the rat has been a valua ...

    SBIRPhase I2010Department of Health and Human Services National Institutes of Health
  7. Tissue-Specific Mutagenesis in Rat as an In Vivo Tool for Colon Cancer Gene Disco

    Amount: $312,628.00

    DESCRIPTION (provided by applicant): The outcome of this SBIR application will be a rat model of colorectal cancer (CRC), which can be used to discover new targets for colon cancer therapy. CRC rats w ...

    SBIRPhase I2009Department of Health and Human Services National Institutes of Health
  8. Creation of hyperactive transposons for mutagenesis in rodents

    Amount: $295,614.00

    DESCRIPTION (provided by applicant): This project aims to rapidly produce rat mutants through a transposon-based method of mutagenesis. The rat is a favored model for many types of human disease for w ...

    SBIRPhase I2009Department of Health and Human Services National Institutes of Health
  9. L1 retrotransposon-based mutagenesis for rat models of human diseases

    Amount: $650,666.00

    DESCRIPTION (provided by applicant): In many aspects the rat is a better animal model than the mouse for functional genomic studies. The physiology and drug metabolism of rats and humans are more simi ...

    SBIRPhase II2007Department of Health and Human Services National Institutes of Health
  10. L1 mutagenesis for mammalian models of human diseases

    Amount: $99,724.00

    DESCRIPTION (provided by applicant): Transposagen is developing an innovative mammalian random mutagenesis system that uses an L1 retrotransposon for direct germ-line mutagenesis. Transposagen's goal ...

    SBIRPhase I2005Department of Health and Human Services National Institutes of Health
US Flag An Official Website of the United States Government